Compare EVOK & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVOK | GXAI |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 8.8M |
| IPO Year | 2013 | 2023 |
| Metric | EVOK | GXAI |
|---|---|---|
| Price | $10.95 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.4K | ★ 94.1K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,424,652.00 | $694,278.00 |
| Revenue This Year | $58.96 | N/A |
| Revenue Next Year | $57.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 67.40 | ★ 23205.74 |
| 52 Week Low | $1.94 | $1.00 |
| 52 Week High | $10.99 | $5.10 |
| Indicator | EVOK | GXAI |
|---|---|---|
| Relative Strength Index (RSI) | 84.66 | 36.55 |
| Support Level | $10.66 | $1.17 |
| Resistance Level | $10.75 | $1.30 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 87.50 | 0.00 |
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.